GeneDx Holdings Corp. (NASDAQ:WGS)
| Market Cap | $1.36B-71.8% |
| Revenue (ttm) | $460.78M+14.6% |
| Net Income | -$111.05M-5431.2% |
| EPS | -$3.76-6366.7% |
| Shares Out | 29.97M |
| PE Ratio | n/a |
| Forward PE | 38.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 912,641 |
| Open | $47.85 |
| Previous Close | $49.24 |
| Day's Range | $45.19 - $49.10 |
| 52-Week Range | $32.21 - $170.87 |
| Beta | 1.99 |
| Analysts | Buy |
| Price Target | $80.25(+76.53%) |
| Earnings Date | Feb 22, 2027 |
About WGS
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating WGS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 22, 2027Earnings report
$WGS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in WGS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by WGS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
WGS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
WGS Revenue by Segment
| Diagnostic test revenue: | $120.06M | 97.46% |
| Other | $3.04M | 2.47% |
| Self-pay patients | $93.00K | 0.08% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New WGS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to WGS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in WGS
| ARKKARK Innovation ETF | $165.00M |
| VTIVanguard Morningstar Total Stock Market ETF | $36.08M |
| ARKGARK Genomic Revolution ETF | $29.14M |
| IWMiShares Russell 2000 ETF | $24.40M |
| VXFVanguard Extended Market ETF | $18.01M |
| FESMFidelity Enhanced Small Cap ETF | $10.59M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from WGS’s recent data — informational, not investment advice
What’s Behind the Score
News check: CEO transition and sequencing adoption gains offset by post-earnings 16.6% stock decline and cash burn concerns.
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 4Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| ARKG | ARK Genomic Revolution ETF | 1.65% |
| GNOM | Global X - Genomics & Biotechnology ETF | 1.09% |
| XHS | State Street SPDR S&P Health Care Services ETF | 0.98% |
| ARKK | ARK Innovation ETF | 0.84% |
| TSME | Thrivent Small-Mid Cap Equity ETF | 0.78% |
| GNMX | Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | 0.60% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 0.50% |
| FSML | Franklin Small Cap Enhanced ETF | 0.37% |
| WCEO | Hypatia Women CEO ETF | 0.37% |
| SSMG | Virtus Silvant Small/Mid Growth ETF | 0.27% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.22% |
| FYC | First Trust Small Cap Growth AlphaDEX Fund | 0.19% |
Weight is the stock’s share of each fund’s holdings.
